ArticleCureus2025
A Primary Liver Cancer Patient Treated With Stereotactic Body Radiation Therapy Using Diaphragm Motion Surrogate Tracking in CyberKnife.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiotherapy (SBRT) is one of the safe and effective treatment options for primary liver cancer. This case report describes a 64-year-old patient diagnosed with primary liver cancer after a contrast-enhanced T1-weighted MRI scan, which revealed a 4.4×5.0 cm mass in the upper segment of the right anterior lobe of the liver. The patient underwent SBRT using diaphragm motion surrogate tracking (DMST) with a dose of 45 Gy delivered in six fractions to the lesion, followed by oral Sorafenib and regular imaging follow-ups. Post-treatment MRI showed that the tumor had shrunk to 0.8cm. This case highlights the efficacy of CyberKnife SBRT in managing liver tumors near the diaphragm dome, achieving a radiographic response. CyberKnife SBRT delivers high-dose radiation to tumors while sparing surrounding normal tissues through high-precision radiotherapy and tracking technologies, particularly suitable for respiratory motion-related lesions. In this case, the patient had a local progression at 23 months and died at 46 months after SBRT. This preliminarily shows the feasibility of integrating DMST into the respiratory motion model for CyberKnife SBRT in treating liver tumors adherent to the diaphragm dome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.